Journal of Neural Transmission

, Volume 113, Issue 11, pp 1787–1790

Brain perfusion effects of cholinesterase inhibitors in Parkinson’s disease with dementia

  • R. Ceravolo
  • D. Volterrani
  • D. Frosini
  • S. Bernardini
  • C. Rossi
  • C. Logi
  • G. Manca
  • L. Kiferle
  • G. Mariani
  • L. Murri
  • U. Bonuccelli
Short Communication

Summary.

Several evidences suggest that cholinergic deficits may significantly contribute to dementia in Parkinson’s disease (PDD) and acetylcholinesterase inhibitors (ChEIs) have been reported to improve cognitive symptoms in PDD, without worsening parkinsonism. Nineteen PDD patients underwent brain perfusion SPECT with 99mTc-ethyl cysteinate dimer after 6 months ChEIs treatment in order to evaluate the functional correlates of clinical improvement. A clear-cut cognitive improvement was reported in PDD patients with a significant improvement of ADAS-cog total score as well as of subscores exploring executive functions (p < 0.01). MMSE total score did not significantly change after ChEIs but the subscore of attention significantly improved after therapy (p < 0.01). No difference in motor performance as evaluated by UPDRS was reported. SPM analysis showed a significant increase of perfusion (p < 0.0001) in bilateral cingulate, and frontal regions after ChEIs. Our data confirm the efficacy of ChEIs in the treatment of dementia associated with PD mainly on attention and executive functions, and the functional findings indicate that this cognitive improvement could be associated with a sort of pharmacological frontal “re-afferentation”.

Keywords: Parkinson’s disease, dementia, SPECT, acetylcholinesterase inhibitors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aarsland, D, Hutchinson, M, Larsen, JP 2003Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementiaInt J Geriatr Psychiatry18937941PubMedCrossRefGoogle Scholar
  2. Aarsland, D, Laake, K, Larsen, JP, Janvin, C 2002Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled studyJ Neurol Neurosurg Psychiatry72708712PubMedCrossRefGoogle Scholar
  3. American Psychiatric Association (APA) (1994) Diagnostic and Statistical Manual of Mental Disorders, IV edn (DSM IV). American Psychiatric Association, Washington. DCGoogle Scholar
  4. Bohnen, NI, Kaufer, DI, Ivanco, LS,  et al. 2003Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease. An in vivo positron emission tomographic studyArch Neurol6017451748PubMedCrossRefGoogle Scholar
  5. Bosboom, JLW, Stoffers, D, Wolters, Ech 2004Cognitive dysfunction and dementia in Parkinson’s diseaseJ Neural Transm11113031315PubMedCrossRefGoogle Scholar
  6. Ceravolo, R, Volterrani, D, Tognoni, G,  et al. 2004Cerebral perfusion effects of Cholinesterase inhibitors in Alzheimer diseaseClin Neuropharmacol27166170PubMedCrossRefGoogle Scholar
  7. Emre, M, Aarsland, D, Albanese, A,  et al. 2004Rivastigmine for dementia associated with Parkinson’s diseaseN Engl J Med35125092518PubMedCrossRefGoogle Scholar
  8. Fournet, N, Moreaud, O, Roulin, J, Naegele, B, Pellat, J 2000Working memory functioning in medicated Parkinson’s disease patients and the effect of withdrawal of dopaminergic medicationNeuropsychology38252271CrossRefGoogle Scholar
  9. Giladi, N, Shabtai, H, Gurevich, T, Benbunan, B, Anca, M, Korczyn, AD 2003Rivastigmine for dementia in patients with Parkinson’s diseaseActa Neurol Scand108368373PubMedCrossRefGoogle Scholar
  10. Glowinski, J 1990Recent finding on dopaminergic transmission in the basal gangliaAdv Neurol536773PubMedGoogle Scholar
  11. Hughes, AJ, Daniel, SE, Kilford, L, Less, AJ 1992Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 casesJ Neurol Neurosurg Psychiatry55181184PubMedCrossRefGoogle Scholar
  12. Leroi, I, Brandt, J, Reich, SG, Lyketsos, CG, Grill, S, Thompson, R, Marsh, L 2004Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s diseaseInt J Geriatr Psychiatry1918PubMedCrossRefGoogle Scholar
  13. Levy, G, Tang, MX, Louis, ED,  et al. 2002The association of incident dementia with mortality in PDNeurology5917081713PubMedGoogle Scholar
  14. Linazasoro, G, Lasa, A, Van Blercom, N 2005Efficacy and safety of donepezil in the treatment of exectuive dysfunction in Parkinson disease: a pilot studyClin Neuropharmacol28176178PubMedCrossRefGoogle Scholar
  15. McKeith, IG, Del Ser, T, Spano, P,  et al. 2000Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international studyLancet35620312036PubMedCrossRefGoogle Scholar
  16. Nakano, I, Hirano, A 1984Parkinson’s disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s diseaseAnn Neurol15415418PubMedCrossRefGoogle Scholar
  17. Nakano, S, Asada, T, Matsuda, H, Uno, M, Takasaki, M 2001Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer’s diseaseJ Nucl Med4214411445PubMedGoogle Scholar
  18. Nobili, F, Vitali, P, Canfora, M,  et al. 2002Effects of long-term Donepezil therapy on rCBF of Alzheimer’s patientsClin Neurophysiol11312411248PubMedCrossRefGoogle Scholar
  19. Pakrasi, S, Mukaetova-Ladinska, EB, McKeith, IG, O’Brien, JT 2003Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in NewcastleInt J Geriatr Psychiatry18879886PubMedCrossRefGoogle Scholar
  20. Perry, EK, Kilford, L, Lees, AJ, Burn, DJ, Perry, RH 2003Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugsAnn Neurol54235238PubMedCrossRefGoogle Scholar
  21. Ravina, B, Putt, M, Siderowf, A,  et al. 2005Donepezil for dementia in Parkinson’s disease: a randomised, double-blind, placebo controlled, crossover studyJ Neurol Neurosurg Psychiatr76903904CrossRefGoogle Scholar
  22. Tiraboschi, P, Hansen, LA, Alford, M,  et al. 2000Cholinergic dysfunction in diseases with Lewy bodiesNeurology54407411PubMedGoogle Scholar
  23. Venneri, A, Shanks, MF, Staff, RT,  et al. 2002Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer’s diseaseNeuroreport138387CrossRefGoogle Scholar
  24. Werber, EA, Rabey, JM 2001The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson’s disease and dementiaJ Neural Transm10813191325PubMedCrossRefGoogle Scholar
  25. Wesnes, KA, McKeith, I, Edgar, C, Emre, M, Lane, R 2005Benefits of rivastigmine on attention in dementia associated with Parkinson diseaseNeurology6516541656PubMedCrossRefGoogle Scholar
  26. Zhou, FM, Wilson, C, Dani, JA 2003Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systemsNeuroscientist92336PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • R. Ceravolo
    • 1
  • D. Volterrani
    • 1
    • 2
  • D. Frosini
    • 1
  • S. Bernardini
    • 1
  • C. Rossi
    • 1
  • C. Logi
    • 1
  • G. Manca
    • 1
    • 2
  • L. Kiferle
    • 1
  • G. Mariani
    • 1
    • 2
  • L. Murri
    • 1
  • U. Bonuccelli
    • 1
  1. 1.Department of NeuroscienceNeurology Section and University of PisaItaly
  2. 2.Nuclear Medicine ServiceUniversity of PisaItaly

Personalised recommendations